For example, BRAF inhibitors vemurafenib and dabrafenib were shown to enable IL-1β secretion by human and murine DCs, but the authors did not explain whether this action on IL-1β was pro- or anti-tumor [114]. The gene discussed is IL1B; the disease is neoplasm.